
According to Benzinga Pro data, during Q4, Adaptimmune Therapeutics (NASDAQ:ADAP) posted sales of $1.42 million. Earnings were up 8.36%, but Adaptimmune Therapeutics still reported an overall loss of $38.86 million. Adaptimmune Therapeutics collected $1.20 million in revenue during Q3, but reported earnings showed a $42.40 million loss.